NCT02178098

Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension

A Placebo-Controlled, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of ETC-1002 in Patients With Hypercholesterolemia and Hypertension

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 143 (actual)
• Sponsor: Esperion Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This Phase 2 study will assess the efficacy and safety of ETC-1002 monotherapy versus placebo in participants with hypercholesterolemia and hypertension.

Conditions

• Hypercholesterolemia
• Hypertension

Interventions

Type	Name	Description
DRUG	ETC-1002	ETC-1002 capsules taken once daily
DRUG	Placebo	Placebo capsules taken once daily

Timeline

• Start date: 2014-06-16
• Primary completion: 2015-05-22
• Completion: 2015-05-22
• First posted: 2014-06-30
• Last updated: 2023-04-04
• Results posted: 2023-04-04

Locations

43 sites across 1 country: United States

Regulatory

• FDA-regulated drug study